Insider Cluster (3 insiders) ·Filed Jun 4, 2026

ALKS

Alkermes plc.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago
Insider cluster: 3 insiders, $1.1M total
Actionable Insight • Neutral

Insider selling is small and routine — no actionable signal. Monitor for any material corporate events (earnings, pipeline updates, M&A) that could trigger more significant insider activity. The historical win rate on ALKS reports is strong (63% at T+20), but this cluster lacks the dollar magnitude to be predictive.

DirectionNeutral
Confidencemedium
Horizondays
Final — all horizons settled through T+60d
ALKS ▲ +9.79% at T+60d
NEUTRAL call ✓ call won +9.79% · α vs SPY +5.79% · entry $42.80 → $46.99
Entry anchored
Jun 4, 2026
via day open
T+1d
-0.82%
call -0.82% · α -1.04%
$42.45
settled 4mo ago
T+5d
+3.46%
call +3.46% · α +2.89%
$44.28
settled 4mo ago
T+20d
+28.83%
call +28.83% · α +26.97%
$55.14
settled 3mo ago
T+60d
+9.79%
call +9.79% · α +5.79%
$46.99
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Three Alkermes insiders, including the EVP R&D/CMO and VP Finance, sold a total of ~$1.15M in open-market sales over a 7-day window. The sales are modest relative to the $7.1B market cap (~0.016%) and include derivative exercises that likely generated shares for sale. No insider buying occurred. The cluster is small in dollar terms and likely reflects routine portfolio diversification and tax-related selling rather than a coordinated bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$1.1M
Insiders
3

Key Facts

  • Total open-market sales: ~$1.15M across 3 insiders
  • Sales represent ~0.016% of Alkermes' $7.1B market cap
  • EVP R&D/CMO Craig Hopkinson sold 9,000 shares ($375K) after exercising 10,000 options
  • VP Finance Samuel Parisi sold 16,217 shares ($687K) after exercising 6,784 options
  • EVP/CLO David Gaffin sold 2,034 shares ($88K) with no accompanying derivative exercise
  • No insider purchases were reported in the cluster window

Financial Impact

Total insider sales of ~$1.15M, or 0.016% of market cap — immaterial relative to company size

insider holdingsdilution

Risk Factors

  • Insider sales could accelerate if upcoming pipeline catalysts disappoint
  • Derivative exercises may signal insiders locking in gains ahead of volatility

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (24 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ALKS-1780606846664
18 reports for ALKS
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +25.88%May 12, 2026
Filters
Rows
Reports for ALKS — sortable, filterable
TypeNow
Sep 16, 2026
16d ago
8-K
NEUTRAL ★ 2/10
$46.07 $42.13▼ −8.55%▼ −11.12%$41.62 (−9.67%)
Sep 3, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$46.10 $45.83▼ −0.59%▲ +0.62%$41.62 (−9.73%)
Aug 3, 2026
8w ago
Insider Cluster
BEARISH ★ 4/10
$49.67 $49.21▲ +0.93%▲ +0.83%$41.62 (+16.22%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$49.67 $49.21▼ −0.93%▼ −0.83%$41.62 (−16.22%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$49.67 $49.21▼ −0.93%▼ −0.83%$41.62 (−16.22%)
Jul 28, 2026
9w ago
8-K
BEARISH ★ 6/10
$50.50 $49.53▲ +1.92%▲ +4.19%$41.62 (+17.59%)
Jul 8, 2026
12w ago
8-K
NEUTRAL ★ 3/10
$54.29 $51.60▼ −4.95%▼ −5.82%$41.62 (−23.35%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$55.14 $51.94▼ −5.80%▼ −6.29%$41.62 (−24.53%)
Jun 4, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$42.80 $44.28▲ +3.46%▲ +2.89%$41.62 (−2.77%)
Jun 1, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$41.19 $44.29▲ +7.53%▲ +10.50%$41.62 (+1.04%)
Showing 10 of 18

US Market Status

Market Open — Closes in 2h 53m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 4, 2026